Form 4: Abbott Laboratories Director Receives Stock Award

Sentiment:

Statement of Changes in Beneficial Ownership


Director Patricia Paola Gonzalez was granted 2,286 restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program.

Summary

  • Director Patricia Paola Gonzalez acquired 2,286 restricted stock units (RSUs) on April 24, 2026.
  • The award was granted under the Abbott Laboratories 2026 Incentive Stock Program.
  • The RSUs will be settled in common shares on a one-to-one basis upon the director's separation from service, death, or a change in control.
  • Following this transaction, the director's total beneficial ownership is 9,205 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment.

Positives

  • The grant aligns the director's long-term interests with those of shareholders through equity-based compensation.

Negatives

  • None identified.

Risks

  • The value of the equity award is subject to future fluctuations in Abbott Laboratories' share price.

Future Outlook

The restricted stock units are scheduled to vest and be paid out upon the director's separation from service, death, or a change in control of the company.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the healthcare and pharmaceutical sectors to ensure alignment between leadership and shareholder interests.

Comparison to Industry Standards

  • The use of restricted stock units for director compensation is consistent with standard practices among S&P 500 companies.
  • The vesting conditions tied to separation from service are common for non-employee director compensation plans.

Stakeholder Impact

  • Shareholders: Minimal impact; represents standard director compensation.

Next Steps

  • The director will hold the restricted stock units until the occurrence of a triggering event such as separation from service.

Key Dates

DateDescription
04/24/2026Date of the restricted stock unit grant transaction.
04/28/2026Date the Form 4 was signed and filed.

Keywords

Abbott Laboratories, ABT, Form 4, Insider Transaction, Director Compensation, Restricted Stock Units

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.